Literature DB >> 19752455

Embolic stroke associated with injection of buprenorphine tablets.

C C Tchoyoson Lim1, Sze Haur Lee, Yee-Choon Wong, Francis Hui.   

Abstract

BACKGROUND: Drug users who crush, dissolve, and inject buprenorphine tablets parenterally may be at risk of severe thromboembolic complications or death. We describe patients with neurologic complications after injecting buprenorphine tablets.
METHODS: Brain MRI including diffusion-weighted imaging (DWI) in patients admitted to the neurologic department after injecting buprenorphine tablets were reviewed.
RESULTS: Seven men had neurologic complications after buprenorphine tablet injection. In 5 patients, multiple small scattered hyperintense lesions were detected on DWI in the cortex, white matter, and basal ganglia of the cerebral hemisphere; one patient had a single small lesion. The side of MRI abnormality corresponded to the side of needle marks on the neck except in one patient who had bilateral injections. One patient, who denied injecting into the neck, had DWI abnormalities in the middle cerebral artery territory on one side and occlusion of the ipsilateral internal carotid artery.
CONCLUSIONS: Buprenorphine tablets can be intentionally or inadvertently injected into the carotid artery, causing a characteristic appearance on diffusion-weighted imaging, consistent with embolic cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752455     DOI: 10.1212/WNL.0b013e3181b784c0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  2 in total

1.  Intravenous melatonin abuse leading to recurrent aortic valve endocarditis: a case report and discussion.

Authors:  Mark B Warren; Jonathan Stabler; Melissa M Hagman
Journal:  BMC Psychiatry       Date:  2016-02-24       Impact factor: 3.630

Review 2.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.